Vaxart, Inc.

Special purpose acquisition corporations did not have a very successful run in the last SPAC wave to hit the life science sector, but a new round of the vehicles that provide companies an alternative

With investors closely watching how biopharmaceutical companies are spending the cash they have on hand so that they do not run out of money in a tough fundraising environment, even firms with revenue

Twelve biopharmaceutical companies announced venture capital financings totaling $672m between 7 and 11 February, which was another relatively quiet week for public company offerings. With biotechnolo

Takeda Pharmaceutical Co. Ltd. is again spinning out a pipeline asset into a new venture with an existing partner, going down the alliance route for its mid-clinical stage norovirus vaccine candidate